Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Effectiveness of interferon-alfa and mid-cycle chemotherapy added to an anthracycline-based regimen in the treatment of aggressive non-Hodgkin's lymphoma
Autore:
Enschede, SH; Shahidi, H; Venugopal, P; Riley, MB; Huang, RW; Jajeh, A; Preisler, HD; Gregory, SA;
Indirizzi:
Rush Canc Inst, Chicago, IL 60612 USA Rush Canc Inst Chicago IL USA 60612Rush Canc Inst, Chicago, IL 60612 USA
Titolo Testata:
LEUKEMIA & LYMPHOMA
fascicolo: 3-4, volume: 40, anno: 2001,
pagine: 325 - 334
SICI:
1042-8194(200101)40:3-4<325:EOIAMC>2.0.ZU;2-R
Fonte:
ISI
Lingua:
ENG
Soggetto:
DIFFUSE HISTIOCYTIC LYMPHOMA; COMBINATION CHEMOTHERAPY; REGROWTH RESISTANCE; CYCLOPHOSPHAMIDE; METHOTREXATE; VINCRISTINE; PREDNISONE; ADRIAMYCIN; BLEOMYCIN;
Keywords:
IFN-alpha & mid-cycle chemotherapy in NHL;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
21
Recensione:
Indirizzi per estratti:
Indirizzo: Enschede, SH Rush Canc Inst, 1725 W Harrison St,Suite 809, Chicago, IL 60612 USA Rush Canc Inst 1725 W Harrison St,Suite 809 Chicago IL USA 60612
Citazione:
S.H. Enschede et al., "Effectiveness of interferon-alfa and mid-cycle chemotherapy added to an anthracycline-based regimen in the treatment of aggressive non-Hodgkin's lymphoma", LEUK LYMPH, 40(3-4), 2001, pp. 325-334

Abstract

Interferon-alfa in combination with cytotoxic chemotherapy has been shown to be effective in treating certain types of non-Hodgkin's lymphoma (NHL) (1). However. there is no published data on upfront induction treatment of aggressive NHL. with IFN-alfa containing regimens. Studies have also shown that one can overcome regrowth resistance by administering mid-cycle agents which slow tumor proliferation between courses of cytotoxic therapy (2). Based on this, we treated 32 consecutive patients between 1/93 and 9/96 with a regimen containing cyclophosphamide 750 mg/m(2), mitoxantrone 12 mg/m(2),and teniposide 60 mg/m(2) IV on day 1 with prednisone 100 mg PO given on days 1-5. On day 15, patients received vincristine 1.4 mg/m(2) (2 mg max.) and bleomycin 10 units/m(2) IV. Interferon-alfa-2b 5x10(6) units/m(2) SQ wasadministered on days 22-26. The median age was 55 (range 26-83), M:F ratiowas 2.5:1. and the median International Prognostic Index was 2.38% of patients had stages I -II and 62% had stages III-IV disease. Fifty-nine percentof the patients achieved a complete response. 22% a partial response, and 19% had progressive disease. The overrall survival (OS) was 81% and the progression free survival (PFS) was 56% at 4.3 years. There were no severe (grade IV) hematologic. flu-like. GI and infectious toxicities from IFN-alpha. Leukopenia was the main severe toxicity related to the chemotherapy regimen (days 1-15), but nor IFN-alpha. Severe infection secondary to the chemotherapy regimen occurred in one patient. Interferon-alfa-2b and mid-cycle chemotherapy added to an anthracycline based regimen is effective induction treatment for patients with aggressive NHL. The OS and PFS using this regimen, based on regrowth resistance, appears to be at least as or more effectivethan CHOP therapy for this group of patients. Severe toxicities were rare.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 05/04/20 alle ore 03:39:13